Showing results (581-590 of 645) with videos related to

Sort By:
Pageof 65
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2018
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN StudyAjay K Gopal, Stephen J Schuster, Nathan H Fowler, et al.
Haematologica|November 30, 2023
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphomaMatthew J Maurer, Carla Casulo, Melissa C Larson, et al.
Blood Advances|November 27, 2024
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO ConsortiumJonathan R Day, Melissa C Larson, Urshila Durani, et al.
Cancer Research|October 6, 2023
XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer CellsRossella Marullo, Sarah C Rutherford, Maria V Revuelta, et al.
Nature Cell Biology|February 21, 2024
Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entitiesTobias Roider, Marc A Baertsch, Donnacha Fitzgerald, et al.
British Journal of Anaesthesia|May 14, 2022
Delivery of drinking, eating and mobilising (DrEaMing) and its association with length of hospital stay after major noncardiac surgery: observational cohort studyCharles M Oliver, Samantha Warnakulasuriya, Dermot McGuckin, et al.
Leukemia & Lymphoma|February 15, 2021
Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphomaNina Orfali, Yuliya Jhanwar, Calvin Koo, et al.
Nature Cell Biology|June 17, 2020
Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levelsTobias Roider, Julian Seufert, Alexey Uvarovskii, et al.
Blood|December 27, 2019
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 resultsJohn C Byrd, William G Wierda, Anna Schuh, et al.
British Journal of Haematology|April 19, 2017
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphomaPeter Martin, Zhengming Chen, Bruce D Cheson, et al.
Pageof 65